Sequenom to Provide Quantitative Gene Expression Services to the Immune Tolerance Network
News May 31, 2007
Sequenom, Inc. has announced that it will provide quantitative gene expression (QGE) services to the Immune Tolerance Network (ITN), a collaborative research organization that solicits, develops, implements and assesses clinical strategies and biological assays for the purposes of inducing, maintaining and monitoring tolerance in humans for kidney, liver and islet transplantation, autoimmune diseases, and allergy and asthma. Financial terms of the contract were not disclosed.
"Our choice of Sequenom's MassARRAY® QGE technology and services is based on testing that demonstrated a high level of accuracy and sensitivity for quantitative gene expression evaluation. Sequenom's services also meet the ITN's assay requirements for reproducibility and quality assurance. Additionally, we are very impressed with the Sequenom scientific team, who demonstrated a thorough understanding of the field and the challenges inherent in gene expression analysis of human clinical samples," said Vicki Seyfert-Margolis, Ph.D., Executive Director, Assay Tolerance Group for ITN.
"Once again, the high sensitivity of the MassARRAY platform, which has enabled the identification of new disease-relevant genes where other systems have failed, is recognized by another world-leading clinical research organization. The ITN, focused on immune tolerance, has joined a growing list of prominent collaborators that rely on our MassARRAY technology for clinical applications," said Harry Stylli, Ph.D., Chief Executive Officer of Sequenom.
"Collaborations such as this demonstrate the high-value proposition of the MassARRAY platform and the QGE multiplexing assay, which allows for high levels of multiplexing and significantly reduces cost per data-point."